Epigallocatechin gallate
- Generic Name
- Epigallocatechin gallate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18O11
- CAS Number
- 989-51-5
- Unique Ingredient Identifier
- BQM438CTEL
- Background
Epigallocatechin gallate has been investigated for the treatment of Hypertension and Diabetic Nephropathy.
- Associated Conditions
- -
- Associated Therapies
- -
EGCG for the Prevention and Treatment of TIPN
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Han Xi Zhao
- Target Recruit Count
- 36
- Registration Number
- NCT06524609
- Locations
- 🇨🇳
Shandong First Medical University Affiliated Cancer Hospital (Shandong Academy of Medical Sciences), Jinan, Shandong, China
Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients
- First Posted Date
- 2023-03-07
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 78
- Registration Number
- NCT05758571
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, Shandong, China
Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 68
- Registration Number
- NCT02580279
Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 83
- Registration Number
- NCT02577393
Study of Topically Applied Green Tea Extract for Radio Dermatitis and Radiation Mucositis
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 15
- Registration Number
- NCT01481818
Effect of EGCG on the Body's Response to Insulin
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- University of Maryland, Baltimore
- Registration Number
- NCT00434499
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath